Incentive motivation in first-episode psychosis: A behavioural study

Murray, Graham K.; Clark, Luke; Corlett, Philip R.; Blackwell, Andrew D.; Cools, Roshan; Jones, Peter B.; Robbins, Trevor W.; Poustka, Luise
January 2008
BMC Psychiatry;2008, Vol. 8, Special section p1
Academic Journal
Background: It has been proposed that there are abnormalities in incentive motivational processing in psychosis, possibly secondary to subcortical dopamine abnormalities, but few empirical studies have addressed this issue. Methods: We studied incentive motivation in 18 first-episode psychosis patients from the Cambridge early psychosis service CAMEO and 19 control participants using the Cued Reinforcement Reaction Time Task, which measures motivationally driven behaviour. We also gathered information on participants' attentional, executive and spatial working memory function in order to determine whether any incentive motivation deficits were secondary to generalised cognitive impairment. Results: We demonstrated the anticipated "reinforcement-related speeding" effect in controls (17 out of 19 control participants responded faster during an "odd-one-out" task in response to a cue that indicated a high likelihood of a large points reward). Only 4 out of 18 patients showed this effect and there was a significant interaction effect between reinforcement probability and diagnosis on reaction time (F1,35 = 14.2, p = 0.001). This deficit was present in spite of preserved executive and attentional function in patients, and persisted even in antipsychotic medication free patients. Conclusion: There are incentive motivation processing abnormalities in first-episode psychosis; these may be secondary to dopamine dysfunction and are not attributable to generalised cognitive impairment.


Related Articles

  • Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Patil, Sandeep T.; Lu Zhang; Martenyi, Ferenc; Lowe, Stephen L.; Jackson, Kimberley A.; Andreev, Boris V.; Avedisova, Alla S.; Bardenstein, Leonid M.; Gurovich, Issak Y.; Morozova, Margarita A.; Mosolov, Sergey N.; Neznanov, Nikolai G.; Reznik, Alexander M.; Smulevich, Anatoly B.; Tochilov, Vladimir A.; Johnson, Bryan G.; Monn, James A.; Schoepp, Darryle D. // Nature Medicine;Sep2007, Vol. 13 Issue 9, p1102 

    Schizophrenia is a chronic, complex and heterogeneous mental disorder, with pathological features of disrupted neuronal excitability and plasticity within limbic structures of the brain. These pathological features manifest behaviorally as positive symptoms (including hallucinations, delusions...

  • Pharmacology of "atypicality" of antipsychotic drugs: status and perspectives. Newman-Tancredi, Adrian; Kleven, Mark S. // Archives of Psychiatry & Psychotherapy;Dec2010, Vol. 12 Issue 4, p5 

    "Atypical" antipsychotics are antagonists at serotonin 5-HT2A and dopamine D2 receptors. However, their effects on negative symptoms and cognitive deficits remain modest and they disrupt metabolic function. Recent drugs, such as aripiprazole, perospirone, bifeprunox, lurasidone and cariprazine...

  • Current Status of Antipsychotic Treatment. Conley, Robert R.; Kelly, Deanna L. // Current Drug Targets - CNS & Neurological Disorders;Apr2002, Vol. 1 Issue 2, p123 

    With the use of chlorpromazine and other traditional antipsychotics for psychosis, it was soon discovered that the antipsychotic efficacy of this class of medications was closely associated with their ability to block dopamine D2 receptors in the brain. This prompted the hypothesis that the...

  • Schizophrenia and Other Psychotic Disorders.  // Current Medical Literature: Psychiatry;2008, Vol. 19 Issue 2, p46 

    The article presents abstracts on schizophrenia and other psychotic disorders, which include progressive brain volume loss in schizophrenia, ethnic stratification of the relation of RGS4 variants with antipsychotic treatment response in schizophrenia, and striatal dopamine synthesis in...

  • National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): Baseline Characteristics. Ismail, M. Saleem; Dagerman, Karen; Tariot, Pierre N.; Abbott, Shana; Kavanagh, Sarah; Schneider, Lon S. // Current Alzheimer Research;Jul2007, Vol. 4 Issue 3, p325 

    CATIE-AD was a multicenter effectiveness trial of atypical antipsychotics in patients with agitation and psychosis associated with AD who resided in the community. The study enrolled 421 participants. In this paper we present and discuss baseline characteristics of participants (demographics,...

  • Modeling “psychosis” in vitro by inducing disordered neuronal network activity in cortical brain slices. Aghajanian, George K. // Psychopharmacology;Nov2009, Vol. 206 Issue 4, p575 

    Dysregulation of neuronal networks has been suggested to underlie the cognitive and perceptual abnormalities observed schizophrenia. An in vitro model of psychosis is proposed based on the two different approaches to cause aberrant network activity in layer V pyramidal cells of prefrontal brain...

  • Metamphetamine Psychosis: How is it Related to Schizophrenia? A Review of the Literature. Sweeting, Melinda; Farrell, Michael // Current Psychiatry Reviews;2005, Vol. 1 Issue 2, p115 

    Background. There is a body of literature on metamphetamine psychosis dating back to the 1950's with a recent resurgence of interest following increase in use worldwide. Distinct similarities appear to exist between metamphetamine psychosis and schizophrenia. Aims. The aim of this paper is to...

  • Schizophrenia: From Dopamine to Glutamate and Back. Carlsson, M. L.; Carlsson, A.; Nilsson, M. // Current Medicinal Chemistry;Feb2004, Vol. 11 Issue 3, p267 

    The first part of the present review describes the exciting journey of dopamine stabilizers, starting in the early eighties with the development of the partial dopamine agonist (-)-3-PPP of phenylpiperidine structure, via various compounds with aminotetraline structure with preferential...

  • Antipsychotic Drugs: Evolving Mechanisms of Action with Improved Therapeutic Benefits. Dean, B.; Scarr, E. // Current Drug Targets - CNS & Neurological Disorders;Jun2004, Vol. 3 Issue 3, p217 

    One of the conundrums of neuropharmacology is to understand the therapeutic mechanisms of action of antipsychotic drugs. Every drug with antipsychotic activity is a dopamine (DA) D2-like receptor antagonist and therefore this function is critical to reducing psychotic symptoms. However, the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics